BCM
PRCT icon

Bayesian Capital Management’s Procept Biorobotics PRCT Stock Holding History

Bayesian Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,704
Closed -$617K – 752
2025
Q2 		$617K Buy
+10,704
New +$605K 0.1% 248
2025
Q1 		– Sell
-9,590
Closed -$772K – 894
2024
Q4 		$772K Buy
+9,590
New +$819K 0.09% 287

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bayesian Capital Management's PRCT Position: Q3 2025 in Review

Bayesian Capital Management sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 10,704 shares — an estimated $617K sold.

Bayesian Capital Management first reported a position in PRCT in Q4 2024 and held it in 2 quarters. The position peaked at $772K in Q4 2024. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • Bayesian Capital Management reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 10,704 Procept Biorobotics shares in Q3 2025, an estimated $617K.
  • Bayesian Capital Management first reported a position in Procept Biorobotics in Q4 2024 and held it in 2 quarters.
  • Bayesian Capital Management's Procept Biorobotics position peaked at $772K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.